Tesla
TSLA
NVIDIA
NVDA
Advanced Micro Devices
AMD
Taiwan Semiconductor
TSM
Qualcomm
QCOM
US Stock MarketDetailed Quotes
INM InMed Pharmaceuticals
- 4.9700
- +0.1700+3.54%
Close Jan 3 16:00 ET
- 5.0000
- +0.0300+0.60%
Pre 07:27 ET
3.60MMarket Cap-0.65P/E (TTM)
4.9899High4.7601Low15.52KVolume4.7700Open4.8000Pre Close76.10KTurnover2.43%Turnover RatioLossP/E (Static)724.15KShares15.696052wk High0.43P/B3.18MFloat Cap2.414052wk Low--Dividend TTM639.06KShs Float3210.0000Historical High--Div YieldTTM4.79%Amplitude2.4000Historical Low4.9020Avg Price1Lot Size
Trending US Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
InMed Pharmaceuticals Stock Forum
InMed Enters Into Standby Equity Purchase Agreement
InMed Pharmaceuticals (NASDAQ: INM) has entered into a Standby Equity Purchase Agreement (SEPA) with YA II PN, , managed by Yorkville Advisors Global LP, on December 13, 2024. The agreement allows InMed to sell up to $10 million of common shares over a 36-month period.
The shares will be priced at 97% of the Market Price during a specified three-day pricing period. The total shares issuable are to 19.99% of...
newsfile· 5 mins ago
Cannabinol modulates distinct endocannabinoid system elements and exerts anti-inflammatory effectsSupports therapeutic potential of cannabinol for inflammatory skin diseases such as psoriasis, atopic dermatitis and pruritusAnti-inflammatory effects of cannabinol show potential for therapeutic and cosmetic application
InMed Announces Share Consolidation to Satisfy Nasdaq Listing Rules
InMed Pharmaceuticals (NASDAQ: INM) has announced a 1-for-20 share consolidation to regain compliance with Nasdaq's listing requirements. The consolidation will reduce outstanding shares from 14,361,550 to approximately 718,078 common shares. The post-consolidation shares are expected to begin trading on Nasdaq Capital Market on November 15, 2024. The trading symbol 'INM' will remain unchanged...
No comment yet